Paul Hastings Advised GenScript and Probio in Series C Financing
Paul Hastings LLP advised GenScript Biotech Corporation (GenScript) (stock code: 1548.HK) and its subsidiary Probio Technology Limited (Probio) in Probio’s Series C financing with investments from Legend Capital, Highlight Capital, Hillhouse (Probio’s Series A investor) and other prominent institutional investors. The share subscription agreement was signed on January 17, 2023. The Series C financing will raise approximately US$224 million at the closing of the transaction. Paul Hastings previously advised GenScript and Probio in 2021 and 2022 on Probio’s Series A and Series B financings, respectively.
GenScript is an industry-leading biotechnology company renowned for its proprietary gene synthesis technology and advanced know-hows in life science research and application. Probio provides comprehensive contract development and manufacturing organization (CDMO) services to biotech and biopharma companies in antibody drug discovery, as well as pre-clinical development, clinical and commercial manufacturing for biologics, and plasmid & virus for therapeutics.
More details on the transaction can be found here.
About Paul Hastings
With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment and real estate, Paul Hastings is a premier law firm providing superior intellectual capital and execution globally to the world’s leading investment banks, asset managers and corporations.